Improving treatment for glioblastoma with MDM2 inhibitors
Official title: Maximizing the efficacy of MDM2 inhibitor therapy for MDM2-amplified glioblastoma
Funded at Mayo Clinic Rochester · NIH-10984798 · Data updated 2026-11-12
This study is looking at how a new treatment called brigimadlin can help patients with a specific type of aggressive brain tumor by making the cancer cells die, and it aims to see if this can lead to better results for those with MDM2-amplified glioblastoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $458,021 |
| NIH project number | 1R01CA285536-01A1 |
| Project ID | NIH-10984798 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who have been diagnosed with MDM2-amplified glioblastoma.
✕Less likely to help
Patients without MDM2 amplification or those with other types of brain tumors may not benefit from this research.
What this research studies
This research focuses on enhancing the effectiveness of MDM2 inhibitor therapy specifically for patients with MDM2-amplified glioblastoma, a type of aggressive brain tumor. The study investigates how these inhibitors can trigger cancer cell death by disrupting the MDM2/p53 pathway, which is crucial for tumor growth. Researchers will explore the mechanisms behind the sensitivity of these tumors to the MDM2 inhibitor brigimadlin, assessing its impact on apoptosis and DNA repair processes. Patients may be treated with this drug to see if it can improve outcomes for those with this specific genetic alteration.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with MDM2-amplified glioblastoma, potentially improving survival rates.
How similar studies have gone: Previous research has shown promising results with MDM2 inhibitors in similar contexts, indicating potential for success in this approach.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Sarkaria, Jann N. — Mayo Clinic Rochester
- Study coordinator: Sarkaria, Jann N.
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.